Welcome to our dedicated page for Solventum Corporation SEC filings (Ticker: SOLV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Solventum Corporation (NYSE: SOLV) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. These documents help investors, analysts and other stakeholders understand Solventum’s financial performance, portfolio actions, capital structure and governance as it operates in the medical instruments and supplies sector.
Solventum uses current reports on Form 8-K to disclose a variety of material events. Examples include 8-K filings reporting quarterly financial results, such as third-quarter 2025 earnings, which incorporate press releases detailing segment performance, non-GAAP measures and updated guidance. Other 8-K filings describe material definitive agreements and their completion, such as the transaction agreement and subsequent closing of the sale of certain assets and liabilities related to Solventum’s purification and filtration business to Thermo Fisher Scientific Inc.
Additional 8-K filings cover capital markets and balance sheet activities, including the commencement, upsizing and pricing of cash tender offers for specified series of senior notes, and an underwriting agreement relating to the sale of shares by a selling shareholder. Governance and leadership changes, such as the appointment of a Chief Commercial Officer and the departure of a segment leader, are also reported on Form 8-K, along with information about related compensation and severance arrangements.
On Stock Titan, users can review these filings alongside AI-powered summaries that explain key points in clear language. This includes highlighting where Solventum discusses its “Transform for the Future” initiative, outlines risk factors, or provides pro forma financial information related to divestitures. The filings page is also a resource for tracking Solventum’s capital allocation strategy, including debt reduction, note tender offers and the authorization of a share repurchase program, as disclosed in its official documents.
Solventum Corp (SOLV) filed an initial ownership report for one of its officers. The reporting person serves as Chief Commercial Officer of Solventum Corp and submitted a Form 3 as an initial statement of beneficial ownership as of 11/10/2025. The filing states that no securities are beneficially owned by this officer at the time of the reported event, and that a power of attorney (Exhibit 24.1) authorizes the attorney-in-fact to sign on the officer’s behalf.
Independent Franchise Partners, LLP filed an amended Schedule 13G (Amendment No. 1) reporting beneficial ownership of 12,899,240 shares of Solventum Corporation common stock, representing 7.44% of the class as of 09/30/2025.
The filer reports 12,626,471 shares with sole voting power and 77,036 with shared voting power. It has 12,899,240 shares with sole dispositive power and 0 with shared dispositive power. The filing certifies the securities were acquired and are held in the ordinary course of business and not with the purpose or effect of changing or influencing control of the issuer.
Solventum Corporation (SOLV) reported Q3 2025 results highlighted by a completed divestiture and significant de-leveraging. The company sold its Purification and Filtration business to Thermo Fisher for approximately $4 billion cash, recording a pre-tax gain of approximately $1.5 billion (net of $86 million in transaction fees). Q3 diluted EPS was $7.22 on total net sales of $2,096 million.
Long-term debt declined to $5,137 million from $7,810 million at year-end, aided by cash tender offers retiring $1.9 billion of senior notes, which produced an $82 million loss on extinguishment (including instruments activity). Cash and equivalents rose to $1,642 million. Operating cash flow for the nine months was $274 million, reflecting the non-cash nature of the $1,518 million gain and working capital movements. The company recognized an unfavorable contract liability of $113 million tied to transition services and recorded a $64 million liability related to a potential payment of up to $75 million associated with the excluded Water Business.
Q3 gross profit was $1,135 million; SG&A was $780 million and R&D was $183 million. Shares outstanding were 173,439,525 as of September 30, 2025.
Solventum Corporation furnished an update on its business by reporting third‑quarter 2025 results and providing the related press release as Exhibit 99.1 under Item 2.02 of a Form 8‑K. The exhibit contains the detailed financial results and commentary. The filing notes the press release is furnished, not filed, under the Exchange Act.
Solventum Corporation appointed Heather Knight as Chief Commercial Officer, effective November 10, 2025. She will oversee global commercial and R&D operations across the MedSurg, Dental Solutions, and Health Information Systems segments, reporting directly to CEO Bryan Hanson.
In connection with the appointment, Chris Barry, Executive Vice President and Group President of MedSurg, will depart effective December 31, 2025. Upon executing and not revoking a general release of claims, he will receive severance benefits under the Solventum Executive Severance Plan, and his outstanding equity awards will be treated under applicable award agreements.
Knight brings 30+ years of MedTech leadership, most recently as COO at Baxter International, with prior roles at Medtronic, Covidien, Tyco Healthcare, and Kendall, and board service at Waters Corporation.
Solventum Corporation filed an 8-K describing updates to its cash tender offers for certain outstanding debt securities. The company reported results as of the early participation date and increased the size of these note tender offers.
Solventum also announced the pricing terms of the tender offers, each described in separate press releases dated September 8, 2025. The company emphasized that the tender offers are being made only under an Offer to Purchase dated August 22, 2025, as amended on September 8, 2025, and only where permitted by applicable law.
Solventum Corp (SOLV) director and Chief Executive Officer Bryan C. Hanson reported changes in his beneficial ownership on 09/01/2025. Hanson had 67,261 restricted stock units (RSUs) vest following conversion of previously granted 3M RSUs into Solventum RSUs under the Employee Matters Agreement; those vested RSUs were recorded at $0 acquisition price. The filing also shows a separate sale of 26,468 common shares at $73.09 each on the same date. After these reported transactions, the filing lists Hanson's direct beneficial ownership as 102,398 shares. The RSUs settle one-for-one into Class A common shares and vest in three equal annual tranches from the grant date; the derivative RSUs list an expiration/related date of 09/01/2033. The Form 4 was signed by an attorney-in-fact on 09/02/2025.
Solventum Corporation completed the sale of its purification and filtration business (excluding its drinking water filtration business) to Thermo Fisher Scientific Inc. under an Amended and Restated Transaction Agreement. Solventum received approximately $4.0 billion in cash at closing, subject to customary adjustments for cash, debt, transaction expenses and working capital. The terms also include a potential payment of up to $75 million from Solventum to Thermo Fisher, either upon a sale of the drinking water filtration business or after an agreed three‑year period. Solventum issued a press release describing the closing, and pro forma financial information giving effect to the transaction is incorporated by reference from a prior filing.
Solventum Corporation has launched cash tender offers to repurchase up to $1,750,000,000 of its outstanding senior notes. The company is offering to buy its 5.450% Senior Notes due 2027, 5.400% Senior Notes due 2029, 5.600% Senior Notes due 2034 and 5.450% Senior Notes due 2031 for a combined purchase price of up to $1,250,000,000, with the 2027 notes capped at $500,000,000. It is also offering to purchase its 6.000% Senior Notes due 2064 and 5.900% Senior Notes due 2054 for up to $500,000,000. The offers are described in an Offer to Purchase dated August 22, 2025 and are subject to stated terms and conditions, including a financing condition.
3M Company reported ownership of 25,569,190 shares of Solventum Corporation common stock, representing approximately 14.75% of the outstanding shares based on 173,387,798 shares outstanding as of July 31, 2025. The filing states that 3M granted Solventum a proxy under a Stockholder and Registration Rights Agreement dated March 31, 2024, so 3M does not exercise voting power over these shares and therefore reports 0 votes while retaining sole dispositive power to sell or direct disposition of the shares.
The Schedule 13G/A was signed on behalf of 3M Company by Kevin H. Rhodes, Executive Vice President, Chief Legal Affairs Officer & Secretary, dated August 18, 2025. The percentage is calculated from Solventum’s August 8, 2025 SEC filing reporting outstanding shares as of July 31, 2025.